Franklin Resources Inc. Invests $5.68 Million in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Franklin Resources Inc. purchased a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) in the 3rd quarter, HoldingsChannel reports. The firm purchased 821,233 shares of the company’s stock, valued at approximately $5,675,000.

A number of other large investors also recently bought and sold shares of the business. nVerses Capital LLC purchased a new position in GoodRx in the 3rd quarter valued at about $33,000. Plato Investment Management Ltd acquired a new position in shares of GoodRx during the second quarter valued at approximately $43,000. EP Wealth Advisors LLC purchased a new position in shares of GoodRx in the third quarter valued at approximately $73,000. Sanctuary Advisors LLC acquired a new stake in shares of GoodRx in the third quarter worth approximately $85,000. Finally, Dark Forest Capital Management LP purchased a new stake in shares of GoodRx during the second quarter worth approximately $86,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Stock Up 1.8 %

Shares of NASDAQ:GDRX opened at $4.52 on Tuesday. The firm’s 50-day moving average is $5.33 and its two-hundred day moving average is $6.96. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. GoodRx Holdings, Inc. has a 1 year low of $4.09 and a 1 year high of $9.26. The firm has a market capitalization of $1.72 billion, a PE ratio of -150.67, a price-to-earnings-growth ratio of 3.54 and a beta of 1.29.

Analysts Set New Price Targets

A number of research analysts have weighed in on GDRX shares. Barclays decreased their price objective on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Citigroup decreased their price target on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Morgan Stanley cut their price objective on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Finally, Mizuho began coverage on GoodRx in a report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GoodRx currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.37.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.